Fig 1.
Validation study design for detection of CIN in HIV-positive women.
In the validation study, which preceded the study presented here, all women were screened with all methods. After screening and diagnosis all women were followed up using study guidelines and local standards of care.
Fig 2.
Strategies for cost-effectiveness analysis comparing cervical screening methods.
Colpo. = colposcopic biopsy, LSIL = low grade squamous intraepithelial lesions, ASCUS = atypical squamous cells of undetermined significance, ASC-H = atypical squamous cells cannot rule out high grade lesion, HSIL = high grade squamous intraepithelial lesions, SCC = Squamous cell carcinoma
Table 1.
Resources utilized to provide screening services.
Table 2.
Caseload scenarios: Total procedures possible per day per study nurse or doctor.
Table 3.
Average estimated procedure costs for each scenario (USD 2013), cost ranges for sensitivity analysis.
Table 4.
Screening outcomes, costs for screening analytic cohort for CIN 2+ (Functional Limit scenario).
Fig 3.
Comparison of screening methods: True cases of CIN2+ detected by cost per case.
NB: The line represents the cost-effectiveness threshold, or frontier. All interventions or combinations of interventions along this line are more cost effective than intervention or combination of interventions left of the line.
Table 5.
Incremental cost-effectiveness analysis (Functional Limit scenario).
Table 6.
Threshold analysis comparing the costs of HPV DNA testing to actual and hypothetical Pap screening (Functional Limit scenario).